{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21","upperLimit":"89","value":"52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The time to platelet engraftment is measured from the time of transplantation until the time of first documented platelet engraftment. Platelet engraftment is defined as a platelet count ≥ 20,000/µL for three consecutive measurements over three or more days. The first of the three days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 3 days or in the following 7 days after the day of engraftment, unless the platelet transfusion is being given specifically to achieve a platelet threshold to allow an elective invasive procedure, such as a central catheter removal.","dispersionType":"Full Range","groups":[{"description":"All patients receive same therapy\n\nFludarabine: 30 mg/m2/day IV x 6 days\n\nMelphalan: 100 mg/m2/day IV x 1 day\n\nTotal Body Radiation: 200 cGy on Day 0\n\nCord Blood: 2 cord blood units IV","id":"OG000","title":"Fludarabine/Melphalan/TBI"}],"paramType":"MEDIAN","populationDescription":"The two participants found to be ineligible after being consented and registered were excluded from the analysis. In addition to those two participants, the 10 participants that did not achieve engraftment were not included in the analysis.","reportingStatus":"POSTED","timeFrame":"From the time of transplantation, until the time of platelet engraftment, median duration of 52 days","title":"Median Time to Platelet Engraftment","type":"SECONDARY","unitOfMeasure":"Days"}